The purpose of this review is to reconsider the significance of BNP as a marker for heart failure in the ARNI era based on the current knowledge of the biochemistry and molecular biology of BNP, the immunoassay methodology used for BNP, the physiological action of neprilysin toward BNP, and the results of recent clinical studies. The gene discussed is NPPB; the disease is heart failure.